NCT05594043View on ClinicalTrials.gov

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

May 21, 2025

Study Completion Date

May 21, 2025

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

MK-6598

Oral tablet

BIOLOGICAL

Pembrolizumab

Intravenous (IV) infusion

Trial Locations (6)

1211

Hôpitaux Universitaires de Genève (HUG) ( Site 0202), Geneva

6500

Ospedale Regionale Bellinzona e Valli ( Site 0200), Bellinzona

9007

Cantonal Hospital St.Gallen ( Site 0203), Sankt Gallen

57104

Sanford Cancer Center ( Site 0300), Sioux Falls

M5G 2M9

Princess Margaret Cancer Centre ( Site 0101), Toronto

H2X 0A9

Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100), Montreal

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY